Gilead HCV drug price 'still far too high for India'

13th February 2014

Reports that Gilead Sciences plans to charge $2,000 in India for 24 weeks of therapy with hepatitis C drug Sovaldi has failed to stop criticism from Medecins Sans Frontieres which claims the price is still far too high.

The biotech has yet to give specifics about the level of tiered pricing it is planning but the Hindu Business Line quoted Gregg Alton, Gilead’s head of corporate and medical affairs, as saying it will cost Indians $2,000, though discussions with patient groups are ongoing. In the USA Sovaldi (sofosbuvir) costs $84,000 for 12 weeks’ treatment, $1,000 per day
Read more at source http://pharmatimes.com/Article/14-02-07/Gilead_HCV_drug_price_still_far_too_high_for_India.aspx#ixzz2t09sxfIU


Leave a Reply

Your email address will not be published.

− 2 = 1

« back to posts